A dexamethasone-treated rat model of cryptosporidiosis was used to evaluate the curative activity of paromomycin. Although eradication of the parasite could not be demonstrated, statistically significant decreases in oocyst excretion and in the intensity of ileal parasitism were observed in animals receiving 100 mg of paromomycin per kg of body weight per day.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC284618 | PMC |
| http://dx.doi.org/10.1128/AAC.38.7.1681 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparative efficacy and safety of anti-cryptosporidial agents: an study on nitazoxanide, halofuginone lactate, KDU731, and paromomycin against .
Front Microbiol
October 2024
Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand.
This study evaluated the effectiveness of anti-cryptosporidial agents nitazoxanide, halofuginone, the pyrazolopyridine analog KDU731, and paromomycin (PMC) in combating the significant zoonotic pathogen . The study utilized HCT-8 host cells to culture and fluorescent microscopy/quantitative PCR (qPCR) for detecting parasitic growth. The efficacy of the compounds was assessed by calculating their inhibitory concentrations (IC) against the total growth of at 48 h post-infection.
View Article and Find Full Text PDFChemical Profiling and Antioxidant, Anti-Inflammatory, Cytotoxic, Analgesic, and Antidiarrheal Activities from the Seeds of Commonly Available Red Grape ( L.).
Nutr Metab Insights
September 2024
Institute of National Analytical Research and Services, Bangladesh Council of Scientific and Industrial Research (BCSIR), Dhanmondi, Dhaka, Bangladesh.
Article Synopsis
- * Researchers evaluated the antioxidant, anti-inflammatory, and pain-relieving properties of the methanolic extract and its fractions using various biological assays, including tests on animal models.
- * The results identified 73 phytoconstituents in grape seed extract, with strong antioxidant effects demonstrated, and confirmed that the extract could significantly reduce pain and diarrhea in tested doses.
Cytokine profiles, blood parasite load and clinical features of visceral leishmaniasis in West Pokot County, Kenya.
Parasitology
June 2024
Department of Medical Microbiology and Infection Prevention, Laboratory for Experimental Parasitology, Amsterdam University Medical Centre, Amsterdam, The Netherlands.
Visceral leishmaniasis (VL) is a severe infectious disease caused by protozoan parasites of the complex. Blood cytokine concentrations in VL patients can inform us about underlying immunopathogenesis and may serve as a biomarker for treatment effectiveness. However, cytokine levels have not yet been studied in VL patients from Kenya, where case load is high.
View Article and Find Full Text PDFInvestigational new drugs for the treatment of leishmaniasis.
Expert Opin Investig Drugs
October 2024
Centre of Experimental Medicine and Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
Introduction: Over the past 20 years, significant progress has been made in anti-leishmanial therapy. Three new drugs/formulations are available for the treatment of various forms of leishmaniasis, namely oral miltefosine, paromomycin and liposomal amphotericin B. However, these advances in drug development have added considerable complexity for clinicians including toxicity, emergence of resistance and decreased sensitivity of available drugs.
View Article and Find Full Text PDFIdentification of FDA-approved drugs that induce heart regeneration in mammals.
Nat Cardiovasc Res
March 2024
Division of Cardiology, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
Targeting Meis1 and Hoxb13 transcriptional activity could be a viable therapeutic strategy for heart regeneration. In this study, we performd an in silico screening to identify FDA-approved drugs that can inhibit Meis1 and Hoxb13 transcriptional activity based on the resolved crystal structure of Meis1 and Hoxb13 bound to DNA. Paromomycin (Paro) and neomycin (Neo) induced proliferation of neonatal rat ventricular myocytes in vitro and displayed dose-dependent inhibition of Meis1 and Hoxb13 transcriptional activity by luciferase assay and disruption of DNA binding by electromobility shift assay.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!